MNKD - MannKind Corp Debt to Book Capitalization Ratio

Graphic logo of MannKind Corp (MNKD)

The daily price action for MannKind Corporation (MNKD) available on the GURU.Markets chart, where the indicator stands at 0.00, is driven by growing interest in non-injectable diabetes therapies. However, the business's financial stability is constrained by slow product adoption and insurance risks. Geopolitical conflicts further exert pressure by disrupting supply chains and closing access to several foreign sales markets.

MNKD (Afrezza) Debt to Book Value history from 07/04/2022 to 10/28/2026

MannKind Corp (MNKD) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Price MannKind Corporation|MNKD - Analyst Consensus Forecast
- market capitalization data:
Market Value Afrezza|MNKD - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share MannKind|MNKD - Company Net Assets|Market Capitalization to Book Value Ratio mannkindcorp.com|MNKD - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio MannKind Corporation|MNKD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity MannKind Corp.|MNKD - Company Cumulative Debt|Debt to Book Value Afrezza|MNKD - Amount of Long-Term Liabilities|Company Short-Term Debts MannKind
Analysis of all company metrics:MNKD MannKind Corporation
Core merchandise of MannKind Corp.

This indicator measures the proportion of borrowed funds within the equity structure, allowing for an assessment of financial stability and the risk of excessive debt load on the business. By analyzing the ratio of total debt to book capitalization, an investor can determine how effectively MannKind Corporation (MNKD) finances the development of its innovative inhalation drug delivery systems and therapy diversification without risking insolvency.

Competitors of MannKind Corporation

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|AMPH - Debts to Book Value|Debt to Book Value Pacira BioSciences PCRX|SPRY - Debt to Book Capital|Debts to Book Capitalization Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Debt to Net Assets Ratio|Debts to Book Capitalization SCPH (scPharmaceuticals, Inc.)|Debts to Book Value TECX|Tonix Pharmaceuticals (TNXP) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio SXTC (sxtchina.com)|Eupraxia Pharmaceuticals Inc. - Debt to Book Capitalization Ratio|Debt to Book Value BioHarvest Sciences, Inc. BHST|Invizyne Technologies, Inc. - Debts to Book Capitalization|ORMP: Debts to Book Capitalization|Debt to Book Capitalization Ratio enterabio.com|HYFT (ipatherapeutics.com) - Debt to Book Value Ratio|Debt to Book Capitalization Ratio ABVC BioPharma, Inc. (ABVC)|Debt to Book Value Ratio CPIX|Debt to Book Capitalization Ratio QNTM|Debts to Book Capitalization FibroGen Corporation (FGEN)|Debts to Book Capitalization TELO|Rani Therapeutics Holdings - Debts to Net Assets|Synergy CHC Corporation (SNYR) - Debt to Book Capitalization Ratio|RLYB - Debt to Book Value Ratio|Debts to Book Capitalization lexariabioscience.com|Debt to Book Value Ratio Pulmatrix Corporation|PTHL - Debt to Book Value|Debt to Net Assets Ratio Aptorum|Debts to Book Capitalization LYRA (Lyra Therapeutics)|Debt to Book Value IBO (Impact BioMedical, Inc.)|TNFA: Debt to Book Capitalization Ratio|cbdMD Inc. - Debts to Book Value|Debt to Book Capitalization Ratio PainReform Ltd. (PRFX)|CYTO: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Lipella Pharmaceuticals, Inc. (LIPO)|OPTN (OptiNose Inc) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio PIRS (Pieris)|Debts to Book Value PROC|Petros Pharmaceuticals (PTPI) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio qlsyy.net (QLI)|Debts to Book Capitalization SLRN (ACELYRIN)|TFFP - Debts to Book Capitalization